Resultats globals: 4 registres trobats en 0.01 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
13 p, 2.2 MB Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer / Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, Joaquim (Hospital Universitari de Girona Doctor Josep Trueta) ; de Aguirre, Itziar (Institut Germans Trias i Pujol) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol) ; Mesia, Carles (Medical Oncology Department, Catalan Institute of Oncology - Hospital Duran i Reynalds, l'Hospitalet de Llobregat, Barcelona, Spain) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ; Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ; García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ; Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Queralt, C. (Institut Germans Trias i Pujol) ; Velarde, Jose María (Institut Germans Trias i Pujol) ; Rosell, Rafael (Institut Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR -T790M mutation (T790M). [...]
2018 - 10.18632/oncotarget.25478
Oncotarget, Vol. 9 (june 2018) , p. 27074-27086  
2.
12 p, 700.5 KB Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain : OSIREX-Spanish Lung Cancer Group / Provencio, Mariano (Universidad Autónoma de Madrid) ; Terrasa, Josefa (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Garrido, Pilar (IRYCIS Hospital Universitario Ramón y Cajal. Medical Oncology Department) ; Campelo, Rosario García (Instituto de Investigación Biomédica A Coruña INIBIC) ; Aparisi, Francisco (Hospital General Universitario de Valencia) ; Diz, Pilar (Complejo Asistencial Universitario de León. Medical Oncology Department León) ; Aguiar, David (Hospital Universitario de Gran Canaria Dr. Negrín. Medical Oncology Department) ; García-Giron, Carlos (Hospital Universitario De Burgos. Medical Oncology Department) ; Hidalgo, Julia (Hospital Lluís Alcanyis. Medical Oncology Department) ; Aguado, Carlos (Hospital Clínico San Carlos (Madrid)) ; González, Jorge García (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ; Esteban, Emilio (Hospital Universitario Central de Asturias. Medical Oncology Department) ; Gómez-Aldavarí, Lorenzo (Complejo Hospitalario Universitario de Albacete) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Juan, Oscar (Hospital Universitari i Politècnic La Fe de Valencia) ; Chara, Luís Enrique (Hospital Universitario de Guadalajara. Medical Oncology Department) ; Marti, Juan L. (Hospital General Universitario de Alicante. Medical Oncology Department) ; Castro, Rafael López (Hospital Clínico Universitario (Valladolid)) ; Ortega, Ana Laura (Complejo Hospitalario de Jaén) ; Moreno, Elia Martínez (Hospital Virgen de la Salud. Medical Oncology Department) ; Coves, Juan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Sánchez Peña, Ana M. (Hospital Universitario de Getafe (Madrid)) ; Bosch-Barrera, Joaquim (Hospital Universitari de Girona Doctor Josep Trueta) ; Gastaldo, Amparo Sánchez (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Núñez, Natalia Fernández (Hospital Universitario Lucus Augusti. Medical Oncology Department) ; del Barco, Edel (Hospital Universitario de Salamanca. Medical Oncology Department) ; Cobo, Manuel (Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Unidad de Gestión Clínica Intercentros de Oncología Médica) ; Isla, Dolores (Hospital Universitario Lozano Blesa. Medical Oncology Department) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Navarro, Fátima (Hospital Universitario Príncipe de Asturias. Medical Oncology Department) ; Calvo, Virginia (Health Research Institute, Hospital Universitario Puerta de Hierro) ; Universitat Autònoma de Barcelona
AURA study reported 61% objective response rate and progression-free survival of 9. 6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to describe the experience with osimertinib in Spain. [...]
2021 - 10.1186/s12885-021-07922-5
BMC Cancer, Vol. 21 (march 2021)  
3.
1 p, 789.3 KB Correction : Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer / Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, Joaquim (Hospital Universitari de Girona Doctor Josep Trueta) ; de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mesia, Carles (Medical Oncology Department, Catalan Institute of Oncology - Hospital Duran i Reynalds, l'Hospitalet de Llobregat, Barcelona, Spain.) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ; Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ; García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ; Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Velarde, Jose María (Institut Germans Trias i Pujol) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
2019 - 10.18632/oncotarget.26855
Oncotarget, Vol. 10 (april 2019) , p. 2576  
4.
12 p, 942.4 KB BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer / Karachaliou, Niki (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Codony-Servat, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Teixidó, Cristina (Pangaea Biotech (Barcelona, Catalunya)) ; Pilotto, Sara (University of Verona (Itàlia)) ; Drozdowskyj, Ana (Pivotal (Madrid)) ; Codony-Servat, Carles (Pangaea Biotech (Barcelona, Catalunya)) ; Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ; Molina-Vila, Miguel Ángel (Pangaea Biotech (Barcelona, Catalunya)) ; Bertrán-Alamillo, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Gervais, Radj (Centre François Baclesse (Caen, França)) ; Massuti, Bartomeu (Hospital General Universitari d'Alacant) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Majem, Margarita (Hospital de Sant Pau (Barcelona, Catalunya)) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; González-Cao, María (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Morales-Espinosa, Daniela (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Verlicchi, Alberto (Ospedale Santa Maria delle Croci (Ravenna, Itàlia)) ; Crisetti, Elisabetta (Institute of Respiratory Diseases. University of Foggia (Itàlia)) ; Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Santarpia, Mariacarmela (Human Pathology Department. University of Messina (Itàlia)) ; Ramírez, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, Joaquim (Hospital Universitari de Girona Doctor Josep Trueta) ; Cardona Zorrilla, Andrés Felipe (Instituto de Oncología de Clínica del Country (Bogotá, Colòmbia)) ; De Marinis, Filippo (Istituto Europeo di Oncologia (Milà, Itàlia)) ; López-Vivanco, Guillermo (Hospital de Cruces (Barakaldo, Biscaia)) ; Sánchez, José Miguel (Hospital Universitario de la Princesa (Madrid)) ; Vergnenegre, Alain (Hôpital du Cluzeau (Limoges, França)) ; Sánchez Hernández, José Javier (Universidad Autónoma de Nuevo León (Mèxic)) ; Sperduti, Isabella (Istituto Regina Elena Cancer Institute (Roma, Itàlia)) ; Bria, Emilio (University of Verona (Itàlia)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abstract. BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. [...]
2015 - 10.1038/srep17499
Scientific reports (Nature Publishing Group), Vol. 7 (December 2015)  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.